Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could fewer heart tests be safer for breast cancer patients?

NCT ID NCT06930521

Knowledge-focused Sponsor: Women's College Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether breast cancer patients on HER2-targeted therapy can safely have fewer heart tests. Currently, patients get heart scans every three months, but most don't change treatment. Researchers will test a personalized schedule based on heart risk, comparing it to the standard approach in 300 patients. The goal is to reduce stress, delays, and costs without compromising heart or cancer outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a more personalized, less burdensome heart monitoring schedule for breast cancer patients, reducing unnecessary tests and healthcare costs.
What could go wrong
This is an early-stage study with only 300 participants, so results may not apply to all patients. There is a small risk that less frequent monitoring could miss early signs of heart damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Jun 2033

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 79 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Stage 1-3 breast cancer (BC). 2. Age 18-79 years. 3. HER-2 positive BC with planned HER2 targeted therapy (HER2TT) for curative intent. Exclusion Criteria: 1. Distant metastases detected clinically, radiographically, or histologically 2. Baseline echocardiogram images of insufficient quality for a quantitative assessment of left ventricular ejection fraction (LVEF) 3. Pre-existing cardiovascular disease, defined as: 1. Prior myocardial infarction (even if LVEF has normalized) 2. Prior heart failure (HF, including patients with preserved ejection fraction and normalized LVEF) 3. Baseline LVEF \<55% 4. Atrial fibrillation 5. Greater than moderate valvular disease (i.e., severe, or moderate-severe) 4. Cumulative anthracycline exposure ≥250mg/m2 before starting HER2TT 5. New York Heart Association Functional Class II, III or IV, or Eastern Cooperative Oncology Group score \>2\* 6. Symptoms potentially due to serious cardiac disease as per investigator's judgement\* \*Exclusion criterion adopted as they make clinical assessment less reliable to detect emergent HF.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm Cardiotoxicity cardiovascular disorder heart failure HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Breast cancer early stage breast cancer (stage 1-3) Cardio-oncology Cardiovascular health Circulatory and respiratory health Clinical and translational cardiovascular sciences Health services and systems - healthcare effectiveness &amp; outcomes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Toronto General Hospital

    RECRUITING

    Toronto, Ontario, M5G 2C4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.